Araghi Mahmood, Mannani Reza, Heidarnejad Maleki Ali, Hamidi Adel, Rostami Samaneh, Safa Salar Hozhabri, Faramarzi Fatemeh, Khorasani Sahar, Alimohammadi Mina, Tahmasebi Safa, Akhavan-Sigari Reza
Department of Pathology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Vascular Surgeon, Department of Surgery, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y.
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in therapeutic approaches, advances in targeted therapy have brought the most successful outcomes in NSCLC treatment. In targeted therapy, antagonists target the specific genes, proteins, or the microenvironment of tumors supporting cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer treatment and the quality of life of patients. Treatment with targeted therapy for NSCLC is changing rapidly due to the pace of scientific research. Accordingly, this updated study aimed to discuss the tumor target antigens comprehensively and targeted therapy-related agents in NSCLC. The current study also summarized the available clinical trial studies for NSCLC patients.
肺癌仍然是全球癌症相关死亡的主要原因。在过去十年中，借助分子转化研究，肺癌尤其是非小细胞肺癌（NSCLC）的诊断和治疗取得了重大进展。在治疗方法的众多有望取得突破的领域中，靶向治疗的进展在NSCLC治疗中带来了最成功的成果。在靶向治疗中，拮抗剂靶向支持癌症生长和存活的肿瘤特定基因、蛋白质或微环境。实际上，通过阻断与肿瘤细胞进展相关的靶基因，可以在不对正常细胞造成明显损害的情况下控制癌症。目前，工作重点一直放在改善靶向治疗方面，以实现令人鼓舞的癌症治疗效果并提高患者的生活质量。由于科研的速度，NSCLC的靶向治疗正在迅速变化。因此，这项更新的研究旨在全面讨论NSCLC中的肿瘤靶抗原和靶向治疗相关药物。本研究还总结了针对NSCLC患者的现有临床试验研究。
